VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Medical Laboratories & Research
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:VNRX
CUSIPN/A
PhoneN/A
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-139.57%
Return on Assets-98.81%
Miscellaneous
EmployeesN/A
Outstanding Shares30,030,000
Market Cap$47.30 million
VolitionRX (NYSEAMERICAN:VNRX) Frequently Asked Questions
What is VolitionRX's stock symbol?
VolitionRX trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."
How were VolitionRX's earnings last quarter?
VolitionRX Ltd (NYSEAMERICAN:VNRX) issued its quarterly earnings results on Monday, August, 13th. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.16) by $0.01. View VolitionRX's Earnings History.
When is VolitionRX's next earnings date?
What price target have analysts set for VNRX?
3 equities research analysts have issued 1-year target prices for VolitionRX's shares. Their predictions range from $5.00 to $10.00. On average, they expect VolitionRX's stock price to reach $7.00 in the next year. This suggests a possible upside of 297.7% from the stock's current price. View Analyst Price Targets for VolitionRX.
What is the consensus analysts' recommendation for VolitionRX?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRX in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VolitionRX.
Who are some of VolitionRX's key competitors?
Who are VolitionRX's key executives?
VolitionRX's management team includes the folowing people:
- Dr. Martin Charles Faulkes, Exec. Chairman (Age 74)
- Mr. Cameron Reynolds, Founder, CEO, Pres & Director (Age 47)
- Dr. Jacob Vincent Micallef Ph.D., MBA, Chief Scientific Officer (Age 62)
- Dr. Jason Bradley Terrell, Chief Medical Officer & CEO of Volition America Inc. (Age 38)
- Mr. Rodney Gerard Rootsaert LLB, Corp. Sec. (Age 47)
Has VolitionRX been receiving favorable news coverage?
News stories about VNRX stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. VolitionRX earned a daily sentiment score of 0.20 on Accern's scale. They also assigned news coverage about the medical research company an impact score of 46.22 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for VolitionRX.
How do I buy shares of VolitionRX?
Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is VolitionRX's stock price today?
One share of VNRX stock can currently be purchased for approximately $1.76.
How big of a company is VolitionRX?
VolitionRX has a market capitalization of $47.30 million.
MarketBeat Community Rating for VolitionRX (NYSEAMERICAN VNRX)
MarketBeat's community ratings are surveys of what our community members think about VolitionRX and other stocks. Vote "Outperform" if you believe VNRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
